This segment encompasses both large multinational pharmaceutical companies including Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca, which maintain captive or semi-captive API supply chains for their branded GLP-1 product portfolios, as well as the rapidly expanding universe of generic pharmaceutical companies across India, China, South Korea, and Eastern Europe that are preparing to launch semaglutide formulations as patent protections expire progressively from 2026 onwards
Keaping a lid on lung cancer: the Keap1-Nrf2 pathway
In addition to our hands-on experience, our testing team has been studying the mens sexual wellness space for nearly two decades, having read through more than 1,000 scholarly articles related to erectile health and various treatments for erectile issues
Management of GERD is possible by visiting doctors on time, lifestyle and dietary modifications, and medications